International Milk Genomics & Human Health Symposium Speaker Program Announced
The speaker program
for the 6th International Symposium on Milk Genomics & Human Health has been released. The three-day event will be held September 28-29, 2009 at the Mercure Paris Porte de Versailles Expo Hotel in Paris, France. The agenda for the 6th annual meeting includes presentations ...
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its financial results and program
IIVS Announces Initiation by EPA of a Pilot Program to Evaluate Non-Animal Eye-Irritation Methods
GAITHERSBURG, Md. , July 30 /PRNewswire-USNewswire/ -- The EPA has initiated a new program
to evaluate the use of non-animal methods to replace the Draize test for eye irritation labeling for antimicrobial cleaning products. The is the first program
of its kind and demonstrates the Ag...
I Walk Because Program Gives Consumers a Voice
- Provide Rich Social Media Experience For WalkMS Participants -
NEW YORK, June 18 /PRNewswire/ -- Reinforcing its commitment to those who support friends, family, and other people living with multiple sclerosis, Saatchi & Saatchi Wellness partnered with Acorda Therapeutics to relaunch t...
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program
in benign prostatic...
AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use
- Webinar on June 9 to discuss the prevalence and prevention of NSAID-induced ulcers available at www.connecttoprotect.com -
BETHESDA, Md. and CHICAGO, June 1 /PRNewswire/ -- The American Gastroenterological Association (AGA) Institute and Horizon Therapeutics, Inc. today launched C...
Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
- Oral Presentation to Highlight Data from Phase II Study Evaluating Bavituximab in Advanced Breast Cancer -
- Poster Presentation to Discuss Data from Phase I Study Evaluating Bavituximab in Multiple Tumor Types -
TUSTIN, Calif., May 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceutical...
Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
PRINCETON, N.J., May 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) is scheduled to host a conference call and live webcast at 4:00 p.m. Eastern Time on Tuesday, June 2, 2009. Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex will provide an updat...
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Cytokinetics Receives Exercise Fee of $50 Million
Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET
SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/ -- Cytokinetics Incorporated (Nasdaq: CYTK ) and Amgen Inc. (Nasdaq: AMGN ) ...
Resverlogix's Success in Inflammation Program Results in 2 Patents Filed
Novel small molecules illustrate potential cost effective approach for
TSX Exchange Symbol: RVX
CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has made s...
Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, received notification from the U.S. Food and Drug Administration (FDA) that the agency has released the Company's CD-N...
SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal
MUNICH, May 15 /PRNewswire/ --
- Investigating the Real Burden of Hypertension, Addressing the
Challenges of Getting to Blood Pressure Goal and SHARE(ing) the Knowledge
( http://www.SHARE-hypertension.com )
The SHARE steering committee announce the launch of Supporting
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
- Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 a.m. PDT -
- Phase 3 CAPACITY results oral presentation, Tuesday, May 19, 3:35 p.m. PDT -
- Conference call and webcast Tuesday, May 19, 6 p.m. PDT -
BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMun...
Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
helps healthcare providers build competence and confidence while keeping infections at bay
DENVER, May 11 /PRNewswire/ -- Medical Simulation Corporation ( MSC ) will launch the SimSuite Central Line Management Program
at AACN's National Teaching Institute (NTI) an...
Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Test for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand CE IVD Test Menu at Booth #611
SUNNYVALE, Calif., April 28 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced speaker and program
highlights for its symposium, " Patient Management in the Era of Ra...
Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology
Catalyst to Provide Proprietary Protein and Small Molecule Products for the Generation and Differentiation of Genomically-Unaltered Induced Pluripotent Stem (iPS) Cells
LA JOLLA, Calif. and BOSTON, April 23 /PRNewswire/ -- Fate Therapeutics, Inc. and Stemgent, Inc. announced today the...
QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
VENLO, Netherlands and KOLKATA, India, April 21 /PRNewswire-Asia/ --
QIAGEN and the Chittaranjan National Cancer Institute (CNCI) today announced a
collaboration to establish the first large-scale cervical cancer screening
program for women in Kolkata, India. QIAGEN (Nasdaq: QGEN ; Frankfur...
AgFeed Industries Enters Into Hog Genetic Program Arrangement with Hypor, the Pig Breeding Division of Hendrix Genetics B.V.
NEW YORK, April 15 /PRNewswire-Asia/ -- AgFeed Industries, Inc. (FEED), one of the largest independent hog production and animal nutrient companies in China, today announced its entry into a genetics program
arrangement with Hypor, a Hendrix Genetics Company. Hypor is world renowned as a leading p...
Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
MELBOURNE, Australia, March 23 /PRNewswire/ -- Cytopia Limited (ASX: CYT) today announced that it will present data on its JAK2 program
at the American Chemical Society Spring meeting, currently underway in Salt Lake City, Utah, USA.
Dr Tracy Nero, Senior Scientist at Cytopia, will be presen...
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that five abstracts from clinical and in-vitro studies of ITMN-191 (R7227) and the company's research programs related to the hepatitis C virus (HCV) have been accepted for presentation at the 44...
Implicit Licenses Clinical Stage Antibody Program From Lilly
BRISBANE, Australia and SEATTLE, Feb. 24 /PRNewswire/ -- Implicit
Bioscience Ltd today announced the acquisition of the clinical-stage
monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an
undisclosed consideration combining cash and stock to Lilly. Lilly will also
DuPont Biotech Stewardship Program Gains External Certification
Third-Party Audit Confirms Responsible Use.
Wilmington, DE (Vocus) February 17, 2009 -- DuPont today announced that third-party audits have verified its plant biotechnology research and development processes are in compliance with the Excellence Through StewardshipSM ...
AMERIGROUP Praises Expansion of State Children's Health Insurance Program (SCHIP)
VIRGINIA BEACH, Va., Feb. 5, 2009 /PRNewswire-FirstCall/ -- AMERIGROUP Chairman and Chief Executive Officer James G. Carlson released the following statement on legislation expanding the State Children's Health Insurance Program
(SCHIP), which was signed yesterday by President Barack Obama:
Transplant Program Tops in Expected One-Year Survival Rate
SEATTLE, Jan. 22 /PRNewswire/ -- Fred Hutchinson Cancer Research Center's
stem-cell transplant program
at the Seattle Cancer Care Alliance (SCCA) was
one of only two transplant programs nationwide that consistently outperformed
the expected one-year survival rate for unrelated donor transplant...
The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates
LANSING, Mich., Jan. 12 /PRNewswire/ -- The Risk Management and Patient
Safety Institute (RM&PSI) today announced its winter and spring 2009 audio
program calendar. The RM&PSI ( http://www.rmpsi.com ), a subsidiary of FinCor
Holdings Inc. ( http://www.fincorholdings.com ), is a nation...
Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
MONTVALE, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US : SYI) has completed enrollment of its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of the Company's compound alagebrium. The study is designed to measure the eff...
Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
EMERYVILLE, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) today announced that Celtic
Pharmaceutical Holdings L.P. (Celtic) has provided an update on XERECEPT(R).
NTI sold the worldwide rights and assets related to XERECEPT to Celti...
Presentation on Cytopia's JAK2 Inhibitor Program in Myeloproliferative Disorders
MELBOURNE, Australia, Dec. 7 /PRNewswire/ -- Data on Cytopia's (ASX: CYT) JAK2 inhibitor CYT387 will be presented at the 50th American Society of Hematology conference in San Francisco. The talk will be presented by Dr Thomas Bumm of Oregon Health and Sciences University and will overview the st...
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- MedImmune today announced that
it has initiated a Phase 2 clinical trial in patients with chronic asthma to
determine the safety of subcutaneous dosing of a humanized monoclonal antibody
(MAb) that targets the interleukin-5 receptor (IL-5R). Preclinical da...
New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema
NEWPORT NEWS, Va., and SAN DIEGO, Dec. 2 /PRNewswire/ -- The Patient
Advocate Foundation (PAF), with support from ImpediMed Ltd. (ASX: IPD), is
pleased to announce the launch of the Lymphedema CareLine (LCL). PAF, through
its MedCare Division, is offering the national, toll-free patient/provider
Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
ST. LOUIS, Nov. 25 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL )
announced today it has entered into a research collaboration program
D-Finitive Cell Technologies, Inc. This collaboration is expected to support
the development and commercial offering of 14 products over a two-yea...
KGI Entrepreneur Program Hosts Angel Investing Educational Meeting
CLAREMONT, Calif., Nov. 24 /PRNewswire/ -- Keck Graduate Institute's (KGI) Biotechnology Entrepreneurship program
today announced it will host an angel investor educational event on Monday, Dec. 8, 2008.
The meeting of Tech Coast Angels (TCA), a network of individual investors who fund ea...
Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics,
Inc. (OTC Bulletin Board: DSKA) will host a teleconference call today at
2:30 p.m. EST to review its drug development programs and financial results
for the third quarter of 2008. Duska's chief executive officer, James S. Kuo,...
Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
Hands-On Science Research Program
Expansion Brings the Amgen Foundation's Total Commitment to Amgen Scholars to $27.5 Million Applications for 2009 Amgen Scholars U.S. Program
THOUSAND OAKS, Calif., Nov. 10 /PRNewswire/ -- Each year, hundreds of
students from across th...
TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai
LA JOLLA, Calif., Nov. 10 /PRNewswire/ -- TorreyPines Therapeutics,
Inc. (Nasdaq: TPTX ) today announced that it has agreed to sell its
Alzheimer's disease genetics research program
to Eisai Co., Ltd. for an
upfront cash payment. TorreyPines and Eisai have collaborated on the
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally
for use in the hospital setting, today announced that it will release its
Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
SUNNYVALE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq:
CPHD) today noted an announcement from Birmingham Children's Hospital
highlighting results using Cepheid's Xpert(TM) MRSA test, which runs on the
GeneXpert(R) System, to implement a screening program
for all patients
Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
Research to be presented Sunday, November 2, 2008 at this year's liver meeting in San Francisco, California, October 31 - November 4
SAN FRANCISCO, Oct. 27 /PRNewswire/ -- Nonalcoholic steatohepatitis
(NASH) is strongly associated with obesity, and there is no approved
medical therapy for...
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
MELBOURNE, Australia, Oct. 27 /PRNewswire/ -- MuriGen Therapeutics
today announced that its collaboration with CSL for the development of a
new class of drugs that target arthritis and other inflammatory diseases
has been restructured.
The collaboration was initially established in February ...
Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From 'Chemobrain'
SAN FRANCISCO, Oct. 24 /PRNewswire/ -- Researchers at 28th annual
National Academy of Neuropsychology (NAN) Conference in New York City this
weekend will present data to help physicians understand more about
cognitive remediation training in breast cancer survivors affected by